Regulations, liability, safety, and economics related to compounding

被引：6

作者：

Campbell, Elliott H. ^{[1
]}

Elston, Dirk M. ^{[2
]}

Straughan, Chad L. ^{[3
]}

Antonovich, Diana D. ^{[2
]}

机构：

[1] Indiana Univ Sch Med, Indianapolis, IN 46202 USA

[2] Med Univ South Carolina, Dept Dermatol & Dermatol Surg, Charleston, SC 29425 USA

[3] Tidewater Pharm & Med Supply, Charleston, SC USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2020年 / 83卷 / 01期

关键词：

botulinum toxin; compounding; cost; economics; financial; formulation; levigation; lidocaine; regulations; regulatory requirements; safety; EXPOSURE; SYRINGES;

D O I：

10.1016/j.jaad.2019.11.061

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Extemporaneous compounding is a means to tailor a medication to an individual patient's needs and may be required when no commercial product exists to meet that need. Compounded products range from buffered lidocaine to topical creams and ointments. Recent heightened regulations have made compounding more challenging for dermatologists and prompted this review of regulations, liability, and safety related to compounding. With this information, providers may minimize liability and maximize safety while caring for their patients.

引用

页码：184 / 188

页数：5

共 21 条

[1] Consensus Statement Regarding Storage and Reuse of Previously Reconstituted Neuromodulators [J].